Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM)
(“Zomedica” or the “Company”), a veterinary diagnostic and
pharmaceutical company, today announced that, subject to the approval of
the TSX Venture Exchange, Johnny D. Powers has been appointed to
Zomedica’s board of directors as an independent director. Additionally,
Powers will also serve as a member of the audit, compensation, and
corporate governance committees of the board of directors.
Powers
has more than 30 years of experience leading business strategy,
operations, sales and marketing, and product development in the human
and pet medical diagnostics markets. Notably, he held executive roles at
animal health industry leader IDEXX Laboratories, Inc. (IDEXX), where,
prior to his retirement, he served as executive vice president
responsible for business performance, product innovation and commercial
effectiveness across multiple point-of-care and reference laboratory
businesses. Currently, Powers is the president and founder of JD Powers
Consulting Group, which provides strategic and executive advisory
services in the healthcare industry.
“I am
excited to be joining Zomedica’s board of directors,” said Johnny D.
Powers. “I look forward to helping Zomedica achieve its goal of
delivering novel diagnostic and therapeutic solutions to the companion
animal market that improve diagnosis and treatment, lower costs, and
enhance outcomes for pet owners and their animals.”
Dr.
Powers holds a bachelor's degree in chemistry from Wake Forest
University, an M.S. in chemical engineering from Clemson University, an
M.B.A. from the Duke University Fuqua School of Business and a Ph.D. in
biochemical engineering from North Carolina State University.
“We
are pleased that a person of Johnny’s stature and reputation in the
animal health industry has agreed to join our Board of Directors and we
look forward to utilizing his expertise and experience as we complete
the development and begin the commercialization of our product
candidates,” said Gerald Solensky Jr., Chairman and CEO, Zomedica.
The
Company also announces that, pursuant to its stock option plan, it has
granted stock options to acquire up to an aggregate of 1,000,000 common
shares of the Company to Powers. All of the stock options vested
immediately upon the date of grant and are exercisable for a two year
term. The stock options are exercisable at the following prices:
500,000 at a price of US$0.26 per share, 100,000 at a price of US$0.35
per share, 100,000 at a price of US$0.45 per share, 100,000 at a price
of US$0.55 per share, 100,000 at a price of US$0.65 and 100,000 at a
price of US$0.75 per share per share.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) (TSX-V: ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) (TSX-V: ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
No comments:
Post a Comment